Why a One-Size-Fits-All Approach to Breast Cancer Prevention Can Leave Women Vulnerable
When Heather Mann learned she had breast cancer, it was a complete surprise. “I had never thought that I was at high risk for breast cancer,” the 49-year-old says. “I don’t have any family lineage or history of breast cancer. My grandmother on my father’s side had breast cancer, but apparently that’s not usually a significant factor. So I was very surprised when I found out that I had a malignant tumor.” Shelia Bauer ‘s breast cancer journey took a very different route. After her twin sisters died of the disease in their 50s, Bauer, now 73, assumed that she likely carried som...
Source: TIME: Health - October 13, 2021 Category: Consumer Health News Authors: Time Tags: Uncategorized Cancer healthscienceclimate Source Type: news

Penn State team secures funding to develop wearable brain scanner
Researchers from Pennsylvania State University have been awarded a two-year...Read more on AuntMinnie.comRelated Reading: Photoacoustic US shows promise for visualizing lymphatic vessels Ultrasound + photoacoustic imaging spot prostate cancer New imaging method could boost ovarian cancer detection Group reveals work on hybrid acoustic-optical imaging Photoacoustic US offers option to thyroid biopsy (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - October 12, 2021 Category: Radiology Source Type: news

Lenvatinib/Pembro Combo for Advanced Anaplastic Thyroid Cancer Lenvatinib/Pembro Combo for Advanced Anaplastic Thyroid Cancer
The nonchemotherapy combination has shown durable responses in patients with metastatic anaplastic thyroid cancer that has progressed on chemotherapy.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 8, 2021 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

FDA Approves Cabozantinib for Differentiated Thyroid Cancer FDA Approves Cabozantinib for Differentiated Thyroid Cancer
The FDA has approved cabozantinib for the treatment of advanced/metastatic differentiated thyroid cancer after disease progression.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 23, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

FDA approves cabozantinib for differentiated thyroid cancer
FDA approved cabozantinib (Cabometyx, Exelixis, Inc.) for patients 12 years of age and older with locally advanced or metastatic differentiated thyroid cancer (DTC) that has progressed following prior VEGFR-targeted therapy and who are ineligible or refractory to radioactive iodine. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - September 22, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Consumer Health: 5 types of thyroid cancer
September is Thyroid Cancer Awareness Month, which make this a good time to learn about the five types of thyroid cancer. More than 44,000 new cases of thyroid cancer will be diagnosed in the U.S. this year, and more than 2,000 people will die of the disease, according to the American Cancer Society. Thyroid cancer occurs in the cells of the thyroid, a butterfly-shaped gland located at the base of your neck. Your thyroid produces… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - September 16, 2021 Category: Databases & Libraries Source Type: news

9/11 First Responders Face Higher Cancer Risk 20 Years Later
Compared with firefighters from other major U.S. cities, researchers found those exposed to the 9/11 disaster had higher risks of both prostate and thyroid cancers. (Source: WebMD Health)
Source: WebMD Health - September 13, 2021 Category: Consumer Health News Source Type: news

ERLEADA ® (apalutamide) Oral Presentations Demonstrate Importance of Prostate Specific Antigen (PSA) as Key Efficacy Indicator and Show Strong Patient Adherence Rates
September 11, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data demonstrating robust prostate-specific antigen (PSA) response and strong adherence rates in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) treated with ERLEADA® (apalutamide) in the real-world clinical setting. The strong PSA response was also seen in a separate post-hoc analysis that showed a correlation between rapid and deep PSA response and prolonged survival in both metastatic castration-sensitive prostate cancer (mCSPC) and nmCRPC. The post-hoc analysis also...
Source: Johnson and Johnson - September 12, 2021 Category: Pharmaceuticals Source Type: news

Janssen Demonstrates Commitment to Advancing Science and Innovation in the Treatment of Solid Tumors at ESMO Annual Congress
September 8, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than ten data presentations from its lung cancer, bladder cancer and prostate cancer portfolio and pipeline will be featured during the European Society for Medical Oncology (ESMO) Annual Congress 2021 virtual meeting, September 16–21. Further details about these data and the science Janssen is advancing will be made available throughout ESMO via the Janssen Oncology Virtual Newsroom.“With a diverse oncology portfolio and pipeline spanning bladder cancer, lung cancer and prostate can...
Source: Johnson and Johnson - September 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Striving to Deliver Better Outcomes: Janssen to Showcase Commitment to Advancing Science for Genitourinary Cancers at AUA 2021
August 31, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today multiple company-sponsored presentations in prostate and bladder cancers will be highlighted at the virtual 2021 American Urological Association Annual Meeting (AUA 2021), September 10-13. “Janssen maintains a strong commitment to advancing innovation and new therapeutic options for patients with genitourinary malignancies. As the treatment of genitourinary cancers becomes more complex, we continue to work with urologists and their teams to improve outcomes for patients across the continuum of disease...
Source: Johnson and Johnson - August 31, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Molecular'Theranostics' Could Guide Treatment in Thyroid Cancer Molecular'Theranostics' Could Guide Treatment in Thyroid Cancer
Patient- and tumor-specific molecular profiles usher in a'new paradigm'for treatment decision-making.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 18, 2021 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

Almost Every Doctor Recommends Sunscreen. So Why Don ’t We Know More About Its Safety?
Each year, as Memorial Day approaches, Holly Thaggard braces herself for the headlines. About how sunscreen may be damaging coral reefs. About the possible flammability of spray-on sunscreen. Headlines—as there were this year—about how sunscreen contains chemicals that could harm your health. “This has happened every single year for the last decade of my life,” says Thaggard, founder of Texas-based Supergoop, a sunscreen company that brands itself as reef-safe and free of hundreds of potentially problematic ingredients. This year, the is-sunscreen-dangerous news cycle started in May, when Valisure, ...
Source: TIME: Health - August 2, 2021 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized healthscienceclimate Public Health Source Type: news

BRAF Mutation in Preoperative Thyroid FNA Specimens BRAF Mutation in Preoperative Thyroid FNA Specimens
Is preoperative BRAF testing useful in guiding the extent of lymph node dissection in papillary thyroid carcinoma?American Journal of Clinical Pathology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 22, 2021 Category: Consumer Health News Tags: Pathology & Lab Medicine Journal Article Source Type: news

Thyroid cancer: Warning signs of the disease you shouldn’t ignore, according to a study
THYROID cancer is diagnosed in about 3,799 people every year in the UK. But advanced technology is now capable of detecting the cancer much sooner than ever before. (Source: Daily Express - Health)
Source: Daily Express - Health - July 20, 2021 Category: Consumer Health News Source Type: news

Thyroid cancer now diagnosed with machine learning-powered photoacoustic/ultrasound imaging
(Pohang University of Science& Technology (POSTECH)) POSTECH Professor Chulhong Kim's research team performs machine learning-powered photoacoustic/ultrasound imaging for thyroid cancer classification. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 9, 2021 Category: International Medicine & Public Health Source Type: news

Thyroid cancer: A worrying gastrointestinal symptom indicating your risk of the disease
THYROID cancer can occur in both men or women at any age. Thousands of patients are being misdiagnosed due to this lesser-known gastrointestinal symptom warning. (Source: Daily Express - Health)
Source: Daily Express - Health - July 7, 2021 Category: Consumer Health News Source Type: news

Radioiodine Therapy Reduces CTCs in Thyroid Cancer Radioiodine Therapy Reduces CTCs in Thyroid Cancer
A new study found a reduction of circulating tumor cell numbers in patients with differentiated thyroid cancer after radioiodine therapy. What are the implications?Clinical Endocrinology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 2, 2021 Category: Consumer Health News Tags: Ob/Gyn & Women ' s Health Journal Article Source Type: news

Impact of High-Quality US in Patients With Thyroid Cancer Impact of High-Quality US in Patients With Thyroid Cancer
What are the differences between community ultrasound and high-quality ultrasound performed by a specialized radiologist?Clinical Endocrinology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 25, 2021 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

Controversies and consensus in thyroid cancer care
(Mary Ann Liebert, Inc./Genetic Engineering News) The American Thyroid Association, the European Association of Nuclear Medicine, the European Thyroid Association, and the Society of Nuclear Medicine and Molecular Imaging released a joint statement on three key topics addressing controversies in thyroid cancer care. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 25, 2021 Category: Cancer & Oncology Source Type: news

Thyroid cancer: The lesser-known warning sign of your risk found in the ear
THRYOID cancer is more common in people in their 30s and those aged over 60. Experiencing a particular sensation in your ear or jaw could indicate your risk. (Source: Daily Express - Health)
Source: Daily Express - Health - June 20, 2021 Category: Consumer Health News Source Type: news

Endocrine Society celebrates Supreme Court decision to uphold the Affordable Care Act
(The Endocrine Society) The Endocrine Society today praised the U.S. Supreme Court's decision to uphold the Affordable Care Act, which makes health care accessible to millions of individuals nationwide, including those with hormone health conditions such as diabetes, osteoporosis, thyroid conditions, and breast and prostate cancer. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - June 17, 2021 Category: International Medicine & Public Health Source Type: news

FDA approves selpercatinib for lung and thyroid cancers with RET gene mutations or fusions
Hematology/Oncology News Burst (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 11, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA approves pralsetinib for RET-altered thyroid cancers
Hematology / Oncology News Burst (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 11, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Filipino-Americans: Vitamin D binding protein in thyroid cancer health disparities
(Impact Journals LLC) Thyroid cancer is one of the most prevalent endocrine cancers. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 9, 2021 Category: International Medicine & Public Health Source Type: news

Targeted therapy pralsetinib safely effectively treats lung and thyroid cancers with RET alterations
(University of Texas M. D. Anderson Cancer Center) Results from the multi-cohort Phase I/II ARROW clinical trial, conducted by The University of Texas MD Anderson Cancer Center researchers, showed that a once-daily dose of pralsetinib, a highly selective RET inhibitor, was safe and effective in treating patients with advanced RET fusion-positive non-small cell lung cancer (NSCLC) and RET-altered thyroid cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 9, 2021 Category: Cancer & Oncology Source Type: news

Cancer symptoms: Expert uncovers five key signs of a growing thyroid tumour
ADVANCED technology is now capable of detecting cancer much sooner than ever before. All suspected thyroid cancers should be screened by an ultrasound, sometimes followed by a biopsy, and all overseen by an expert surgeon. (Source: Daily Express - Health)
Source: Daily Express - Health - June 5, 2021 Category: Consumer Health News Source Type: news

Study finds wide variation in costs of thyroid cancer care
There's a wide variation in cost and transparency of payer-negotiated prices for thyroid cancer care, according to a study published Friday in JAMA. (Source: Health News - UPI.com)
Source: Health News - UPI.com - June 4, 2021 Category: Consumer Health News Source Type: news

Wide variation in cost and transparency of payer-negotiated prices for thyroid cancer care
(Brigham and Women's Hospital) Since Jan. 1, 2021, hospitals in the US have been required by The Centers for Medicare and Medicaid Services (CMS) to provide pricing information online about items and services. A team of researchers from Brigham and Women's Hospital and Massachusetts Eye and Ear leveraged the newly available data to analyze price transparency and price variation for the treatment of thyroid cancer. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 4, 2021 Category: International Medicine & Public Health Source Type: news

Janssen Highlights Commitment to Advancing Transformative Innovations in Oncology with Scientific Updates from Deep, Diverse Pipeline and Portfolio at ASCO and EHA Virtual Scientific Programs
June 1, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 30 company-sponsored studies, including six oral presentations, will be featured during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, June 4-8. Janssen presentations will include new data and updates for both approved and investigational therapeutics that are being studied for the treatment of various solid tumors and blood cancers. Immediately following ASCO, additional data will be featured during the European Hematology Association (EHA) Virtual Congress, June 9-17. A ...
Source: Johnson and Johnson - June 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

The LUCA device proves its readiness for a better thyroid cancer screening
(ICFO-The Institute of Photonic Sciences) The study recently published in Biomedical Optics Express and authored by members of the consortium reports on several study cases and clinical tests conducted to validate the accuracy and high quality of measurements achieved by the LUCA device. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 31, 2021 Category: Cancer & Oncology Source Type: news

Long-Term ERLEADA ® (apalutamide) Patient-Reported Outcomes Data in Metastatic Castration-Sensitive Prostate Cancer Demonstrate Maintenance of Health-Related Quality of Life for Patients
May 26, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced patient-reported outcomes (PRO) data from the pre-specified final analysis of the Phase 3 TITAN study in patients with metastatic castration-sensitive prostate cancer (mCSPC). The TITAN study previously demonstrated statistically significant improvement in overall survival (OS) after a median follow-up of 44 months in patients receiving ERLEADA® plus androgen deprivation therapy (ADT).1 The new PRO data showed that the addition of ERLEADA® to ADT maintained patients’ health-related quality of lif...
Source: Johnson and Johnson - May 26, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

AffyImmune Therapeutics' AIC100 Granted Fast Track Designation for Treating Thyroid Cancer
NATICK, Mass., May 17, 2021 -- (Healthcare Sales & Marketing Network) -- AffyImmune Therapeutics, Inc., a clinical stage biotechnology company finding safe, effective ways to use CAR T cells against solid cancers, announced today that the US Food and Drug... Biopharmaceuticals, Oncology, FDA AffyImmune Therapeutics, immunotherapy, Thyroid Cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 17, 2021 Category: Pharmaceuticals Source Type: news

How Long Can You Live With Stage IV Thyroid Cancer?
Title: How Long Can You Live With Stage IV Thyroid Cancer?Category: Diseases and ConditionsCreated: 5/14/2021 12:00:00 AMLast Editorial Review: 5/14/2021 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - May 14, 2021 Category: Cancer & Oncology Source Type: news

Why this life sciences leader is stepping away from the CEO seat — and what she plans to do next
The CEO was a cofounder of the diagnostics company 14 years ago, starting with a thyroid cancer test that has helped more than 100,000 patients avoid surgeries. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - May 10, 2021 Category: Biotechnology Authors: Ron Leuty Source Type: news

Why this life sciences leader is stepping away from the CEO seat — and what she plans to do next
The CEO was a cofounder of the diagnostics company 14 years ago, starting with a thyroid cancer test that has helped more than 100,000 patients avoid surgeries. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - May 10, 2021 Category: American Health Authors: Ron Leuty Source Type: news

Are There Stages of Thyroid Cancer?
Title: Are There Stages of Thyroid Cancer?Category: Diseases and ConditionsCreated: 4/30/2021 12:00:00 AMLast Editorial Review: 4/30/2021 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - April 30, 2021 Category: Cancer & Oncology Source Type: news

How Is Thyroid Cancer Detected?
Title: How Is Thyroid Cancer Detected?Category: Diseases and ConditionsCreated: 4/28/2021 12:00:00 AMLast Editorial Review: 4/28/2021 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - April 28, 2021 Category: Cancer & Oncology Source Type: news

A New Frontier in Papillary Thyroid Cancer Treatment A New Frontier in Papillary Thyroid Cancer Treatment
What is the best course of treatment for small, low-risk papillary thyroid cancer? New developments have created opportunities to deliver care in a more individualized manner.American Thyroid Association (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - April 26, 2021 Category: Radiology Tags: Diabetes & Endocrinology Commentary Source Type: news

International research teams explore genetic effects of Chernobyl radiation
(NIH/National Cancer Institute) Researchers utilized genomic tools to investigate potential health effects of exposure to ionizing radiation, a known carcinogen, as a result of the 1986 Chernobyl accident. One study found no evidence that genetic changes associated with radiation exposure are passed to children, while the second study documented the genetic changes in the tumors of people who developed thyroid cancer after being exposed as children or fetuses to the radiation released by the accident. Findings are being published close to the 35th anniversary of the Chernobyl disaster. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 22, 2021 Category: Cancer & Oncology Source Type: news

Janssen Provides Update on Phase 3 ACIS Study in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with ERLEADA ® (apalutamide) and ZYTIGA® (abiraterone acetate) Plus Prednisone Combination
RARITAN, N.J., April 19, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that regulatory submissions based on the Phase 3 ACIS study, which evaluated the combination of ERLEADA® (apalutamide) and ZYTIGA® (abiraterone acetate) plus prednisone in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC), will not be pursued. As presented at the American Society of Clinical Oncology’s Genitourinary (ASCO GU) Cancers Symposium in February 2021, the ACIS study met its primary endpoint of radiographic progression-free survival (rPFS); ho...
Source: Johnson and Johnson - April 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

ATA Issues Guidelines for Managing Anaplastic Thyroid Cancer
Evidence - based guidelines address diagnosis, evaluation, and treatment, including early multidisciplinary care team involvement (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - April 16, 2021 Category: Cancer & Oncology Tags: Endocrinology, Oncology, Pathology, Pharmacy, Radiology, Journal, Source Type: news

ATA Issues Guidelines for Managing Anaplastic Thyroid Cancer
FRIDAY, April 16, 2021 -- In new guidelines issued by the American Thyroid Association and published in the March issue of Thyroid, recommendations are presented for the diagnosis, evaluation, and treatment of anaplastic thyroid cancer (ATC). Keith... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 16, 2021 Category: Pharmaceuticals Source Type: news

Low-Risk Thyroid Cancer: No Benefit of Postsurgical Iodine Low-Risk Thyroid Cancer: No Benefit of Postsurgical Iodine
Forgoing postoperative radioactive iodine in low-risk differentiated thyroid cancer is supported by phase 3 data.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 8, 2021 Category: Cancer & Oncology Tags: Diabetes & Endocrinology News Source Type: news

Outcomes in Lymph Node Metastases of Thyroid Cancer Outcomes in Lymph Node Metastases of Thyroid Cancer
Should active surveillance be considered for thyroid cancer patients with cervical lymph node metastases?Clinical Endocrinology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 2, 2021 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

Increase in Thyroid Cancer Rates Points to Overscreening Increase in Thyroid Cancer Rates Points to Overscreening
Large but variable increases in rates of papillary thyroid cancer in many countries over the past two decades may point to the"diagnostic pressure" of opportunistic high-sensitivity screening, say experts.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 15, 2021 Category: Cancer & Oncology Tags: Diabetes & Endocrinology News Source Type: news

First lab-grown mini-thyroids use patients' own tissue
(International Society for Stem Cell Research) To investigate potential alternative treatment strategies for patients with hypothyroidism, researchers have now for the first time succeeded in generating thyroid mini-organs in the lab. In a new study published in Stem Cell Reports, Robert Coppes and colleagues from the University of Groningen, The Netherlands, used healthy thyroid tissue from patients undergoing surgical removal of the thyroid to grow mini-thyroid organs in a lab which resembled thyroid glands in their structure and protein content. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 11, 2021 Category: Cancer & Oncology Source Type: news

Could Too Much Light at Night Raise Your Odds for Thyroid Cancer?
(Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - February 10, 2021 Category: Cancer & Oncology Tags: Endocrinology, Oncology, News, Source Type: news

Too Much Light at Night May Raise Odds for Thyroid Cancer
A new study ties an overabundance of nighttime artificial light with an elevated risk of thyroid cancer. (Source: WebMD Health)
Source: WebMD Health - February 10, 2021 Category: Consumer Health News Source Type: news

Could Too Much Light at Night Raise Your Odds for Thyroid Cancer?
WEDNESDAY, Feb. 10, 2021 -- Though living in a bustling urban area may have its upside, all those nighttime lights could come at a price to your health, new research suggests. The study, published online recently in Cancer, a peer-reviewed journal... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - February 10, 2021 Category: General Medicine Source Type: news

Could Too Much Light at Night Raise Your Odds for Thyroid Cancer?
Title: Could Too Much Light at Night Raise Your Odds for Thyroid Cancer?Category: Health NewsCreated: 2/10/2021 12:00:00 AMLast Editorial Review: 2/10/2021 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - February 10, 2021 Category: Cancer & Oncology Source Type: news